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Background: Fifty percent of people living with human immunodeficiency virus (HIV) or 
acquired immunodeficiency syndrome (AIDS) worldwide are female. In Brazil, for example, 
240,000 women are infected with HIV , rates of infection in women have increased over the last 
two decades, and addressing HIV prevention and treatment for women at risk for, or living with, 
HIV/AIDS remains a challenge. To better address the needs of women living with HIV in Brazil, 
the Instituto de Pesquisa Clínica Evandro Chagas – Fundação Oswaldo Cruz (IPEC-FIOCRUZ) 
HIV Women’s Cohort was established in 1996 to study the natural history of women seeking 
HIV care. This analysis describes the characteristics of women in the cohort who participated 
in HIV clinical trials between 1999 and 2008.
Methods: A total of 736 Women’s Cohort participants were in active follow-up and 665 par-
ticipants from the Women’s Cohort were included in univariable and multivariable analyses to 
determine socioeconomic and sociodemographic factors associated with women’s participation 
in HIV clinical trials at our site.
Results: Of the complete cohort, 23% participated in a clinical trial between January 1999 and 
July 2008. Odds of participation decreased for women who were younger than 35 years old, cur-
rently employed, had an HIV-positive sexual partner, and/or who reported a lifetime history of 
illicit drug use. Alternatively, the odds of participation increased for women who had more than 
8 years of formal education, were living independently, and/or were married or cohabitating.
Conclusion: The rate of participation in HIV clinical trials by women in the IPEC-FIOCRUZ 
Cohort was similar to other published cohorts, but identification of local risk factors and bar-
riers to participation remains important. Our analysis offers a novel description of the factors 
associated with participation in HIV clinical trials among women in care at IPEC-FIOCRUZ 
in Rio de Janeiro, Brazil.
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Background
For more than a decade, women have comprised half of all people living with human 
immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) – an 
estimated 15.9 million women worldwide in 2009. One-third of all HIV-infected persons 
in Central and South America live in Brazil, 240,000 of whom are women.1 Brazil’s 
proactive national response to providing prevention and treatment services has kept 
overall infection rates stable and has significantly decreased mortality.2 Rates of infec-
tion among women, however, have increased, with a shift in male-to-female infection 
rates from 15:1 in 1986 to 1.5:1 in 2002. Since 2002, the male-to-female infection 
rate has stabilized.3,4 Among persons aged 13–19 years, a ratio reversal in the num-
ber of AIDS cases has occurred, with 0.8:1 male-to-female AIDS cases reported.4 HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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With 29% of women aged 15–24 reporting onset of sexual 
activity before the age of 15,1 addressing HIV prevention and 
treatment for women at risk for, or living with, HIV/AIDS 
in Brazil remains a   challenge. Despite this, prior to 2007, 
monies were not allocated for HIV/AIDS programs target-
ing women (other than for the prevention of mother-to-child 
transmission) in Brazil.4
In recent years, increased awareness of the need for 
representative inclusion of women in HIV clinical trials has 
emerged, and this has been a priority of the UNAIDS (Joint 
United Nations Programme on HIV/AIDS) Global Coalition 
on Women and AIDS since its inception in 2004. This need 
stems both from increasing numbers of women living with 
HIV worldwide, and differences between men and women 
in terms of: clinical outcomes, including safety and efficacy; 
pharmacokinetic profiles of antiretroviral therapies (ARTs); 
socioeconomic factors; and barriers to care and prevention.
Not unexpectedly, factors associated with women’s par-
ticipation in clinical trials seem to vary by geographic region 
and community, with little data published on the participation 
of women in Central and South America. This is problematic, 
as the successful development of future HIV programs and 
policies targeting women is dependent upon addressing the 
needs of women within individual communities. This analysis 
was designed to assess factors contributing to HIV clinical 
trial participation among women in the Instituto de Pesquisa 
Clínica Evandro Chagas – Fundação Oswaldo Cruz (IPEC-
FIOCRUZ) Women’s Cohort.
Materials and methods
Study population
Since 1986, investigators at the IPEC-FIOCRUZ, a large 
referral center for HIV research and care in Rio de Janeiro, 
Brazil, have provided care to HIV-positive men and women. In 
1996, the IPEC-FIOCRUZ Women’s Cohort was established 
to study the natural history of women seeking care at their 
site. Criteria for inclusion in the cohort include documentation 
of HIV-positive status and willingness and ability to provide 
informed consent. Cohort procedures have been described in 
previously published analyses.5–7 A total of 764 women were 
enrolled in the cohort between May 1996 and July 2008. Of the 
764 women enrolled, 28 women died or were lost to follow-up 
prior to the opening of the first HIV clinical trial at IPEC-
FIOCRUZ in January 1999, and never had the opportunity to 
participate in clinical trials. A total of 736 women were in active 
follow-up between January 1999, when the first HIV clinical 
trial opened, and July 2008. Since that time, 34 HIV prevention 
and therapy trials have been open to enrollment for women. 
This analysis was performed to describe the characteristics of 
women in the cohort who participated in HIV clinical trials 
between 1999 and 2008, as well as to assess whether these 
women were representative of the IPEC-FIOCRUZ Women’s 
Cohort as a whole, or whether certain populations of women 
should be targeted to equalize representation in our trials.
Selection of subjects
IPEC-FIOCRUZ HIV Women’s Cohort participants who had 
a documented visit after January 1, 1999 were assessed for 
this study. All cohort participants that did not participate in 
a clinical trial contributed to this analysis. For women that 
participated in a clinical trial, we excluded those without 
cohort baseline data within 1 year of enrollment in a trial. 
This exclusion criterion was created to represent sociode-
mographic and socioeconomic factors near the time of trial 
enrollment as accurately as possible. Baseline demograph-
ics at the time of clinical trial entry could not be included 
in this analysis because different trials collected different 
demographic information. The combined total number of 
women who did not participate in a clinical trial and those 
that participated and had cohort baseline data within 1 year of 
enrollment in a clinical trial were included in the analysis of 
factors associated with participation in clinical trials. A flow 
chart describing subject selection is provided in Figure 1.
All procedures were approved by the IPEC-FIOCRUZ 
institutional review board, and all participants were willing 
and able to provide informed consent.
Covariates
Covariates selected for univariable analysis were: age; race/
ethinicity (self-reported; White/non-White); years of formal 
  education; employment status (yes/no); independent living 
status (yes/no; this variable refers to subject’s ability to pro-
vide her own independent housing versus living in the home 
of her family or friends; it does not refer to cohabitation or 
roommate status); married or living as married (yes/no); 
presence of an emotional or financial support from a network 
(yes/no); number of living children; children living with HIV/
AIDS (yes/no); substance use (alcohol and illicit drugs) (yes/
no); history of sexual abuse (yes/no); history of domestic 
violence (yes/no); sexual partner’s HIV status (yes/no); and 
partner’s substance abuse or dependence (yes/no).
Statistical analysis
The primary objective was to identify factors associated with 
the participation of women in clinical trials at the FIOCRUZ 
site. The primary outcome was the dichotomous participation HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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of women in clinical trials. Women who did not participate 
served as the internal control group.
Covariate selection was performed via a multistep process 
using the strategy proposed by Bursac.8 First, univariable 
analysis was performed using the chi-square test for 
categorical variables, and the analysis of variance method for 
continuous variables. The threshold for inclusion in the initial 
multivariable logistic regression model was set at P , 0.25. 
Only those women with complete datasets were included in 
the multivariable model.
Collinearity was assessed for among covariates that were 
statistically significant in the univariable analysis; tolerance 
values below 0.40 were considered as having high multicol-
linearity (Allison9). Therefore, variables included in the 
multivariable model were both significant in the univariable 
analysis and had a tolerance value greater than or equal 
to 0.40.
The Wald statistic and likelihood ratio test were then per-
formed to test the appropriateness of removing each variable 
from the multivariable model. Confounders were defined as 
variables that, when removed, resulted in a .20% change 
in the beta coefficient of any other variable. Variables were 
removed pass-by-pass, starting with the highest P value. A 
P # 0.10 to enter criterion was set as the threshold to retain 
the variable in the model (first stage). Variables considered 
confounders were retained in the model. In the second stage, 
variables with P . 0.25 in the univariable analysis were 
entered into the model. Criteria to retain variables in the final 
model were the same as in the first stage of multivariable 
analysis. Model fitness was verified through calculation of 
the Akaike information criterion and the degree of statistical 
dispersion. Overdispersion was not present.
Residual analysis was performed using the deviance, 
Pearson residuals, and Cook’s distances, as well as leverage 
Women’s cohort participants in active follow-up
after 01/01/1999
N = 736 (187 participations)
Analysis unit: Number of women
(not number of participations)
CT = Clinical Trial
Exclusion criteria: Difference between
enrollment dates in CT and in
women’s cohort ≤1 year
N = 71
Outcome:
Did the
women
participate
in a CT?
331 women were
screened for a CT
171 women were eligible
160 women were 
 not eligible
YES
NO
Were the
women eligible
for the CT?
+
565 did not participate in a CT 100 women participated in a CT
405 women were not
screened for a CT
Figure 1 IPeC-FIOCRUZ (Instituto de Pesquisa Clínica evandro Chagas – Fundação Oswaldo Cruz) Women’s Cohort: screening and participation in clinical trials. Rio de 
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graphics. Univariable analysis was conducted using SPSS 
Statistics (IBM Corporation, Somers, NY) software 13.0, and 
R 2.10.0 software was utilized in the multivariable analyses.
Results
Cohort characteristics
Of women who were in active cohort follow-up between 
January 1, 1999 and October 7, 2008 (n = 736), 331 (45.0%) 
were approached for participation in at least one clinical trial; 
51.7% of those approached (23.2% of the complete cohort, or 
n = 171/736) were eligible and enrolled in at least one clinical 
trial. A total of 7.0% (n = 12/171) enrolled in more than one 
clinical trial, with a total of 187 subject participations over 
the 9-year period (Figure 1). A total of 85/171 women par-
ticipated in ART-naïve clinical trials, 72/171 participated in 
trials for ART-experienced subjects, and 16/171 participated 
in trials where ART status requirements were not defined. 
A list of trials offered at our site between January 1999 and 
October 2008 is provided in Table 1.
Participant characteristics
A total of 665 of the 736 cohort participants were included 
in the analysis; 100 women participated in a clinical trial and 
had baseline cohort data obtained within 1 year of enroll-
ment into a trial; 71 women were excluded from the analysis 
because they participated in a clinical trial more than 1 year 
after cohort enrollment. Characteristics of subjects included 
in the analyses are summarized in Table 2. The mean age 
was 35 years, and most women were non-White, unem-
ployed, had 8 years or less of formal education, reported not 
having any kind of emotional or financial support, were not 
cohabitating with a partner, lived independently, and had at 
least one living child. Nearly two-thirds of women reported 
having a sexual partner of negative or unknown HIV status. 
Fewer than 50% had a partner who was an illicit drug user 
or had self-reported alcohol consumption or illicit drug 
use. A history of sexual abuse and/or domestic violence 
was common.
One hundred women (15.0%) participated in at least one 
clinical trial; mean CD4 count and HIV-1 viral load were 
225 cells/mm3 (standard deviation [SD] 171 cells/mm3, 
median 206 cells/mm3) and 236,504 copies/mL (SD 445,713 
copies/mL, median 77,319 copies/mL), respectively.
Univariable analysis
A comparison of categorical variables between women who 
did and did not participate in clinical trials is also presented 
in Table 2. Women who participated in clinical trials were 
more likely to be 36–45 years old, have greater than 8 years 
of formal education, be unemployed, and live independently, 
but less likely to be married or cohabitating, have a sexual 
partner that was known to be HIV-positive or actively using 
substances, or have a personal history of illicit drug use (all 
P , 0.05). A history of sexual abuse (P , 0.10) and alcohol 
consumption (P , 0.25) were believed to be confounding 
issues, and were also entered into the multivariable models.
Multivariable logistic regression analysis
The final multivariable logistic regression model depicts 
independent predictors of participation in clinical trials by 
Table  1  number  of  women  enrolled  in  each  clinical  trial 
conducted at IPeC-FIOCRUZ (1999–2008)
Clinical trial  
number
Year of  
enrollment
Number  
of women
ART-naïve TMC 278 2005 5
2nn 2001 4
A5175 2005 35
A5221 2007 2
AI 424-138 2006 2
2007 1
BI 1882.33 2004 2
CAn 30021 2001 6
CAn 30024 2001 3
ePV 2001 2000 6
HPTn052 2005 19
ART- 
experienced
A 431-1006 2003 9
A 431-1022 2005 1
AI 424-008 2000 7
AI 424-044 2001 4
AI 424-045 2002 3
AI 424-067 2004 5
BI 1182-48 2003 1
CROWn 2000 8
M06-802 2007 3
M98-888 2000 2
MK-005 2005 5
MK-019 2006 1
PRO 317 2001 6
TMC114-C215 2004 3
  2005 4
TMC114-C229 2008 5
TMC125-C206 2006 6
TMC125-C217 2005 2
2008 1
TMC125-C227 2005 1
TMC214-C215 2005 1
VICTOR e-3 2006 7
no ART  
requirement
FUJISAWA 2002 10
ML18743 2006 6
Abbreviations: ART, antiretroviral therapy; IPeC-FIOCRUZ, Instituto de Pesquisa 
Clínica evandro Chagas – Fundação Oswaldo Cruz.HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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the 585 women in our cohort with complete data (Table 3). 
Women who participated in clinical trials were more likely 
to: have greater than 8 years of formal education (adjusted 
odds ratio [AOR] = 2.28; P = 0.001), be married or cohabi-
tating (AOR = 1.96, P = 0.007), and be living independently 
(AOR = 1.69, P = 0.059). Women were less likely to have 
participated in a clinical trial if they: were less than 35 years 
of age (AOR = 0.29, P , 0.001), were currently employed 
(AOR = 0.50, P = 0.006), had an HIV-positive sexual part-
ner (AOR = 0.43, P = 0.002), or reported illicit drug use 
(AOR = 0.52, P = 0.035).
Discussion
In 1993, the US National Institutes of Health mandated 
the participation of women in clinical trials,10 and the US 
Food and Drug Administration repealed its exclusion of 
women of childbearing age in trials,11,12 setting a global 
precedent. Since then, with the help of the UNAIDS 
Global Coalition on Women and AIDS, awareness of the 
need for equitable inclusion of women in prevention and 
therapeutics trials has increased worldwide. Overall, 23% 
of the IPEC-FIOCRUZ Women’s Cohort participated in a 
Table 2 Selected baseline characteristics of women according to 
participation in clinical trials
Variable Participated in a clinical trial
Noa n (%) Yesa n (%) Totala
Total number 565 100 665
Ageb
 # 35 years 294 (55.1) 33 (33.7) 327 (51.7)
  36–45 years 161 (30.1) 48 (49.0) 209 (33.1)
 $ 46 years 79 (14.8) 17 (17.3) 96 (15.2)
Skin color
  White 237 (44.4) 44 (44.9) 281 (44.5)
  non-White 297 (55.6) 54 (55.1) 351 (55.5)
educationb
 . 8 years 215 (40.6) 51 (53.1) 266 (42.5)
  #8 years 315 (59.4) 45 (46.9) 360 (57.5)
employment statusb
  employed 256 (47.9) 34 (35,1) 290 (46.0)
  not employed 278 (52.1) 63 (64.9) 341 (54.0)
Has emotional or financial support?
  Yes 320 (60.2) 64 (65.3) 384 (61.0)
  no 212 (39.8) 34 (34.7) 246 (39.0)
Lives independentlyb
  Yes 342 (65.4) 76 (77.6) 418 (67.3)
  no 181 (34.6) 22 (22.4) 203 (32.7)
Married or living as marriedb
  Yes 206 (38.6) 49 (50.0) 255 (40.3)
  no 328 (61.4) 49 (50.0) 377 (59.7)
Has an HIV-positive partnerb
  Yes 214 (40.5) 25 (25.8) 239 (38.2)
  no 315 (59.5) 72 (74.2) 387 (61.8)
Has a partner who uses drugsb
  Yes 77 (14.4) 5 (5.1) 82 (13.0)
  no 457 (85.6) 93 (94.9) 550 (87.0)
number of living children
  none 92 (17.7) 17 (17,3) 109 (17.6)
  1–2 298 (57.2) 61 (62.2) 359 (58.0)
 . 3 131 (25.1) 20 (20.4) 151 (24.4)
Children living with HIV/AIDS
  Yes 48 (9.8) 7 (7.3) 55 (9.4)
  no 386 (78.8) 74 (77.1) 460 (78.5)
  Childless 56 (11.4) 15 (15.6) 71 (12.1)
History of sexual abusec
  Yes 109 (20.6) 12 (12.4) 121 (19.3)
  no 420 (79.4) 85 (87.6) 505 (80.7)
History of domestic violence
  Yes 184 (35.0) 32 (33.3) 216 (34.8)
  no 341 (65.0) 64 (66.7) 405 (65.2)
Any alcohol consumptiond
  Yes 214 (40.1) 32 (32.7) 246 (38.9)
  no 320 (59.9) 66 (67.3) 386 (61.1)
Lifetime illicit drug useb
  Yes 152 (28.5) 17 (17.3) 169 (26.7)
  no 382 (71.5) 81 (82.7) 463 (73.3)
Notes: aTotal values are not the same for all variables as a consequence of missing 
values; bP value , 0.05; cP value , 0.10; dP value , 0.25.
Abbreviations:  AIDS,  acquired  immunodeficiency  syndrome;  HIV,  human 
immunodeficiency virus.
Table 3 Multiple logistic regression for women’s participation in 
clinical trials, IPeC-FIOCRUZ, Brazila
Variable Adjusted odds  
ratio (95% CI)
P-value
Age
 # 35 years 0.29 (0.17–0.50) ,0.001
  36–45 years 1.00
 $ 46 years 0.78 (0.39–1.51) 0.475
education
 . 8 years 2.28 (1.40–3.76) 0.001
 # 8 years 1.00
employment status
  employed 0.50 (0.30–0.81) 0.006
  Unemployed 1.00
Lives independently
  Yes 1.69 (1.00–2.98) 0.059
  no 1.00
Married or living as married
  Yes 1.96 (1.20–3.22) 0.007
  no 1.00
Has an HIV-positive partner?
  Yes 0.43 (0.25–0.73) 0.002
  no 1.00
Lifetime illicit drug use
  Yes 0.52 (0.28–0.93) 0.035
  no 1.00
Note: a11.7% (78/665) of women who had a missing value in at least one variable 
selected from univariable analysis was excluded.
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; IPEC-
FIOCRUZ, Instituto de Pesquisa Clínica evandro Chagas – Fundação Oswaldo Cruz.HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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clinical trial between   January 1999 and July 2008. While 
there is little published data on the participation of women 
in HIV clinical trials in other parts of Central and South 
America, these values are similar to rates of participation 
seen between 1993 and 1998 in the Canada Women’s HIV 
Study.13
In our cohort, the odds of participation in an HIV clini-
cal trial decreased for women who were younger than 35 
years old, were currently employed, had an HIV-positive 
sexual partner, and who reported a lifetime history of illicit 
drug use. However, the odds of participation in an HIV clini-
cal trial increased for women who had more than 8 years 
of formal education, were living independently, and were 
married or cohabitating.
Decreased rates of participation by women younger 
than 35 years of age may reflect the exclusion by many 
trials of women who are pregnant, desire to become preg-
nant, or are nursing. Since data on safety in pregnancy 
often lags behind efficacy data for novel therapeutic agents, 
this obstacle is difficult to overcome for therapeutics trials. 
However, attempts can be made to increase the number of 
women under 35 in HIV prevention trials where the inter-
vention is not of potential harm to a fetus (ie, behavioral 
interventions), and in other trials when contraception is 
readily available for women who choose not to become 
pregnant.
Years of formal education has been shown to be pre-
dictive of trial participation for both men and women,13,14 
which may reflect literacy requirements, access to care, 
and/or an overall sense of empowerment in directing one’s 
health care (although these factors have not explicitly been 
explored). Feelings of empowerment have previously been 
documented as a reason for participation in trials, particu-
larly in   communities where HIV infection remains highly 
stigmatized13 and/or access to care is poor. Since 1996, 
universal access to care and combination ART has been 
available to all HIV-infected Brazilians, eliminating access 
to care as a primary motivation for trial participation. Access 
to experimental medications, however, remains a potential 
motivating factor, especially for those drugs being developed 
for salvage therapy.
Employment status was inversely correlated with 
trial participation in our cohort. Because Brazil prohibits 
monetary compensation for participation in clinical trials, 
financial incentive did not confound our analysis. Rather, 
unemployment may correlate with an increased availabil-
ity to comply with study visits and procedures. Similarly, 
having an HIV-positive or substance-abusing partner may 
reflect a woman’s role as caregiver and/or earner for her 
family, which, like employment, could decrease her ability 
to participate in a trial and comply with study schedules 
and procedures.
Unmarried status has been shown to be a risk factor for the 
acquisition of HIV and other sexually transmitted infections 
in women in Brazil and elsewhere,16–18 a finding that may arise 
from a number of factors, including: increased number of 
sexual partners, decreased ability to negotiate safer sex, and 
decreased health awareness. Lack of participation in clinical 
trials may reflect a similar lack of self-health promotion, or 
other factors such as the lack of a social support network. 
Our study, however, was not designed to elucidate reasons 
for nonparticipation.
Other factors associated with clinical trial participation 
have also been studied. History or current use of injection 
drugs is consistently a predictor of trial nonparticipation,13,19–21 
as it was in our cohort. In the USA and Canada, Caucasian 
ethnicity has been shown to be a predictor of participation 
in trials.13,14,19,20,22 Participants in our cohort were more likely 
to be non-White by self-report, a finding we believe reflects 
the high prevalence of multiethnic persons at our referral 
center. In keeping with previously published data, the need 
for conscious recruitment of ethnic minorities in all com-
munities remains critical.
Limitations
This analysis is not without limitations. First, a complete 
medical and social history is taken at the time of   enrollment 
in our cohort, and data on select items is updated every 
6 months thereafter. Updated information for all covari-
ates, however, is not re-obtained at the time of trial enroll-
ment. In an effort to improve the accuracy of our data and 
its relevance to a participant’s decision-making process, 
we excluded women from the analysis who did not have 
a Women’s Cohort baseline visit within 1 year of enter-
ing a trial. Second, subjects were not specifically asked 
why they decided to participate in a clinical trial or not. 
We also do not have data on the proportion of men from 
our clinical site that agree to participate or be screened for 
clinical trials as a reference category. Finally, this analy-
sis was not stratified by study type, and factors predicting 
trial participation are likely to vary between therapeutic, 
biomedical prevention, and behavioral intervention trials. 
The potential barriers to care indentified in this analysis 
are, however, instrumental in shaping future recruitment HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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efforts and designing trials to better serve the needs of our 
patient population.
The 565 women who did not participate in clinical trials 
included both subjects who were screened but not eligible for 
a clinical trial (n = 160), and subjects who were not screened 
for or offered participation in a clinical trial (n = 405). 
Women are routinely prescreened for participation at our 
site, and the refusal rate of those approached to participate 
is very low. Therefore, most women who were screened 
but found to be ineligible were believed to be eligible by 
prescreening but developed an exclusion criterion between 
prescreening and screening. The decision to screen in our 
cohort is based upon entry criteria for currently available 
studies, and should not be subject to physician bias in the 
same way that failure to approach a woman for participa-
tion could be.
Women that were not screened for a clinical trial may 
not have been asked to participate for a variety of reasons. 
First, women would not have been asked to participate if the 
prescreening process determined them to be ineligible. This 
is often the case for women that are well controlled on their 
current ART, as many of our studies target treatment-naïve 
patients or those in need of salvage therapy. Second, women 
were asked to participate based on the type of trial being 
conducted. Therefore, women on ART could not have been 
asked to participate, for example, if only treatment-naïve 
studies were available at a given time. Third, women may 
have been eligible for but not asked to participate if the num-
ber of female or total enrollment slots was limited. Lastly, 
some women may not have been approached to participate 
for reasons not captured above (physician preference, etc).
Conclusion and future directions
Our analysis offers a novel description of the factors associ-
ated with the participation of women in HIV clinical trials 
at IPEC-FIOCRUZ in Rio de Janeiro, Brazil. Because the 
participation of women in HIV clinical trials varies greatly 
with geography and sociodemographic makeup, ongoing 
local assessment of recruitment and retention barriers is 
important for ensuring future success in enrolling adequate 
numbers of women in HIV clinical trials. This is particularly 
important for communities in Central and South America 
and other communities whose needs have not yet been well 
described. By ensuring the adequate representation of women 
in clinical trials, we hope to achieve the goal of optimizing 
care and minimizing toxicities and comorbidities for women 
living with HIV .
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